J Lexchin

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi Investigator experiences with financial conflicts of interest in clinical trials
    Paula A Rochon
    Women s College Research Institute at Women s College Hospital, Toronto, Canada
    Trials 12:9. 2011
  2. ncbi Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines?
    J Lexchin
    Emergency Department, Toronto Hospital, Ont
    CMAJ 156:351-6. 1997
  3. ncbi Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence
    Joel Lexchin
    School of Health Policy and Management at York University, Toronto, Canada
    Int J Health Serv 34:101-22. 2004
  4. ncbi Pharmaceutical industry sponsorship and research outcome and quality: systematic review
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada M3J 1P3
    BMJ 326:1167-70. 2003
  5. ncbi Transparency in drug regulation: mirage or oasis?
    Joel Lexchin
    Emergency Department, University Health Network, School of Health Policy and Management, York University, Toronto, Ont
    CMAJ 171:1363-5. 2004
  6. ncbi Drug withdrawals from the Canadian market for safety reasons, 1963-2004
    Joel Lexchin
    School of Health Policy and Management, York University, Emergency Department, University Health Network, Toronto, ON
    CMAJ 172:765-7. 2005
  7. ncbi Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto
    Int J Health Serv 35:237-56. 2005
  8. ncbi A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, Ont, and Emergency Department, University Health Network, Canada
    Health Policy 79:214-20. 2006
  9. ncbi New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?
    Joel Lexchin
    School of Health Policy and Management at York University, Toronto, Ont
    Can Fam Physician 48:1487-92. 2002
  10. ncbi Are drugs too expensive in Canada? Yes
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ont
    Can Fam Physician 52:573-6, 578-81. 2006

Detail Information

Publications58

  1. ncbi Investigator experiences with financial conflicts of interest in clinical trials
    Paula A Rochon
    Women s College Research Institute at Women s College Hospital, Toronto, Canada
    Trials 12:9. 2011
    ..We obtained information from investigators about adherence to practices that minimize the introduction of such bias in their clinical trials experience...
  2. ncbi Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines?
    J Lexchin
    Emergency Department, Toronto Hospital, Ont
    CMAJ 156:351-6. 1997
    ..Although the Pharmaceutical Advertising Advisory Board's Code of Advertising Acceptance avoids many of the deficiencies of the PMAC code, it, too, has weaknesses. Proposals for strengthening the enforcement of both codes are offered...
  3. ncbi Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence
    Joel Lexchin
    School of Health Policy and Management at York University, Toronto, Canada
    Int J Health Serv 34:101-22. 2004
    ..Cost sharing also leads to patients foregoing essential medications and to a decline in health care status...
  4. ncbi Pharmaceutical industry sponsorship and research outcome and quality: systematic review
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada M3J 1P3
    BMJ 326:1167-70. 2003
    ....
  5. ncbi Transparency in drug regulation: mirage or oasis?
    Joel Lexchin
    Emergency Department, University Health Network, School of Health Policy and Management, York University, Toronto, Ont
    CMAJ 171:1363-5. 2004
  6. ncbi Drug withdrawals from the Canadian market for safety reasons, 1963-2004
    Joel Lexchin
    School of Health Policy and Management, York University, Emergency Department, University Health Network, Toronto, ON
    CMAJ 172:765-7. 2005
  7. ncbi Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto
    Int J Health Serv 35:237-56. 2005
    ..The article concludes with some alternative recommendations on the future of IPRs...
  8. ncbi A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, Ont, and Emergency Department, University Health Network, Canada
    Health Policy 79:214-20. 2006
    ..This study uses a convenience sample of new drugs marketed in the United States and determines how many of these products are initially unavailable in Canada and their therapeutic value...
  9. ncbi New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?
    Joel Lexchin
    School of Health Policy and Management at York University, Toronto, Ont
    Can Fam Physician 48:1487-92. 2002
    ..To determine how many randomized controlled trials on the safety or efficacy of new drugs are published when these drugs are first marketed in Canada, and to determine the quality of the information in those trials...
  10. ncbi Are drugs too expensive in Canada? Yes
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ont
    Can Fam Physician 52:573-6, 578-81. 2006
  11. ncbi Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ont
    CMAJ 174:1120-1. 2006
  12. ncbi Effects of restrictive formularies in the ambulatory care setting
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Canada
    Am J Manag Care 8:69-76. 2002
    ..To determine the consequences of restrictive formularies in the ambulatory care setting in 4 areas: overall drug expenditures, overall healthcare spending, changes in the quality of prescribing, and health outcomes...
  13. ncbi How patient outcomes are reported in drug advertisements
    J Lexchin
    Emergency Department, Toronto Hospital, Ontario
    Can Fam Physician 45:1213-6. 1999
    ..To examine how changes in outcomes are reported in drug advertisements in medical journals...
  14. ncbi What information do physicians receive from pharmaceutical representatives?
    J Lexchin
    Can Fam Physician 43:941-5. 1997
    ..To assess the information pharmaceutical sales representatives provide to physicians...
  15. ncbi The effect of generic competition on the price of brand-name drugs
    Joel Lexchin
    Emergency Department, University Health Network, Toronto, Ont, Canada
    Health Policy 68:47-54. 2004
    ..Literature from the US has shown that brand-name manufacturers do not compete on price once generic competitors become available. This study was undertaken to investigate if this is also true in Canada...
  16. ncbi Medicine reimbursement recommendations in Canada, Australia, and Scotland
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, Ontario, Canada M3J 1P3
    Am J Manag Care 14:581-8. 2008
    ....
  17. ncbi Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, ON M3J 1P3, Canada
    Health Policy 91:142-7. 2009
    ..This paper investigates the pricing strategy (perfect flat pricing, perfect monotonic pricing, intermediate) used for multiple dosage medications listed in the Ontario Drug Benefit Formulary...
  18. ncbi Assessing the quality of drug detailing
    William Molloy
    Geriatric Research Group, McMaster University, Hamilton Health Sciences, Henderson Site, 711 Concession Street, Ontario, Canada
    J Clin Epidemiol 55:825-32. 2002
    ..64, P <.0001, presentation time, F(2, 118) = 9.98, P <.0001, pharmaceutical representative, F(4, 118) = 9.58, P <.0001, and physician rating the detail, F(109, 118) = 1.94, P <.0001...
  19. ncbi The secret things belong unto the Lord our God: secrecy in the pharmaceutical arena
    Joel Lexchin
    School of Health Policy and Management, York University
    Med Law 26:417-30. 2007
    ..By treating data on efficacy and safety as commercially confidential information they effectively collude with industry in denying health professionals and the public access to essential information to be able to use drugs appropriately...
  20. ncbi Rebuttal: are drugs too expensive in Canada?
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ont
    Can Fam Physician 52:841-2, 843-5. 2006
  21. ncbi Stop the merry-go-round
    Joel Lexchin
    School of Health Policy and Management, York University Toronto, Ontario, Canada
    Healthc Pap 4:29-34. 2004
    ..A full public pharmacare plan with first-dollar coverage will increase public expenditures but reduce overall drug costs and distribute benefits more equitably...
  22. ncbi Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON M3J 1P3, Canada
    Ann Pharmacother 40:2216-22. 2006
    ..Since the early- to mid-1990s, drug companies have paid fees for a variety of activities carried out by the Therapeutic Products Directorate in Canada and the Therapeutic Goods Administration in Australia...
  23. ncbi Clinical trials in Canada: whose interests are paramount?
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    Int J Health Serv 38:525-42. 2008
    ..If clinical trials are to serve the purpose for which they are designed, developing reliable and objective information about new drugs, then commercial interests cannot be allowed to take precedence over health interests...
  24. ncbi Physician awareness of drug cost: a systematic review
    G Michael Allan
    Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada, 2 Institute of Health Economics, Edmonton, Alberta, Canada
    PLoS Med 4:e283. 2007
    ..We designed this systematic review to investigate doctors' knowledge of the relative and absolute costs of medications and to determine the factors that influence awareness...
  25. ncbi Is there still a role for spontaneous reporting of adverse drug reactions?
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ont
    CMAJ 174:191-2. 2006
  26. ncbi Poor reporting of scientific leadership information in clinical trial registers
    Melanie Sekeres
    Kunin Lunenfeld Applied Research Unit, Baycrest, Toronto, Ontario, Canada
    PLoS ONE 3:e1610. 2008
    ..Identifying those scientifically responsible for trial conduct increases accountability. The objective is to examine the proportion of registered clinical trials providing valid scientific leadership information...
  27. ncbi Bigger and better: how Pfizer redefined erectile dysfunction
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Ontario, Canada
    PLoS Med 3:e132. 2006
  28. ncbi National evaluation of policies on individual financial conflicts of interest in Canadian academic health science centers
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    J Gen Intern Med 23:1896-903. 2008
    ..Conflicts of interest (COI) in research are an important emerging topic of investigation and are frequently cited as a serious threat to the integrity of human participant research...
  29. ncbi Qualitative research and the politics of knowledge in an age of evidence: developing a research-based practice of immanent critique
    Eric Mykhalovskiy
    York University, Toronto, ON, Canada
    Soc Sci Med 67:195-203. 2008
    ..The latter include challenges to managerial claims about neo-liberal health reform and broadening the evidentiary terrain upon which interlocutors can participate in public debate about health care restructuring...
  30. ncbi Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies
    Joel Lexchin
    York University, Toronto, Canada
    Soc Sci Med 70:643-7. 2010
    ..Under this model COI would be prohibited on the grounds that it might influence the outcome of regulatory decisions...
  31. ncbi Commercial influence and the content of medical journals
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada
    BMJ 332:1444-7. 2006
  32. ncbi Regulating drugs for effectiveness and safety: a public health perspective
    Julie M Zito
    Pharmaceutical Health Services Department, University of Maryland, Baltimore, Maryland 21201, USA
    Med Care 45:911. 2007
  33. ncbi Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy
    Barbara Mintzes
    Centre for Health Services and Policy Research, University of British Columbia UBC, Vancouver, BC Canada V6T 1Z3
    Res Social Adm Pharm 1:310-30. 2005
    ..This article describes a survey of Canadian drug policy experts carried out in 2001, during one such legislative review. The survey results are compared to more recent DTCA policy developments...
  34. ncbi Voluntary self-regulatory codes: what should we expect?
    Joel Lexchin
    York University
    Am J Bioeth 3:49-50. 2003
  35. ncbi Will lower drug prices jeopardize drug research? A policy fact sheet
    Donald W Light
    University of Medicine and Dentistry of New Jersey, USA
    Am J Bioeth 4:W1-4. 2004
  36. ncbi Is Australia's national medicines policy failing? The case of COX-2 inhibitors
    Agnes Vitry
    Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia
    Int J Health Serv 37:735-44. 2007
    ....
  37. ncbi Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs
    Alan Cassels
    School of Health Information Science, University of Victoria, Victoria, BC
    CMAJ 168:1133-7. 2003
    ..We assessed newspaper descriptions of drug benefits and harms, the nature of the effects described and the presence or absence of other important information that can add context and balance to a report about a new drug...
  38. ncbi The pharmaceutical industry as a medicines provider
    David Henry
    School of Medical Practice and Population Health, Faculty of Health, University of Newcastle, New South Wales, Australia
    Lancet 360:1590-5. 2002
    ..Better access to essential drugs may be achieved through voluntary licensing arrangements between international pharmaceutical companies and manufacturers in developing countries...
  39. ncbi Information about a discontinued drug
    Joel Lexchin
    CMAJ 178:730. 2008
  40. ncbi Foreign free riders and the high price of US medicines
    Donald W Light
    Department of Psychiatry, University of Medicine and Dentistry of New Jersey, 40E Laurel Road, Stratford, NJ 08084, USA
    BMJ 331:958-60. 2005
  41. ncbi Do higher drug costs lead to better health?
    Barbara Mintzes
    Can J Clin Pharmacol 12:e22-7. 2005
    ..For "newer" to truly mean "better", fundamental changes are needed to the regulations governing market approval and post-approval surveillance. Such changes are possible, but would require strong political will...
  42. ncbi Physician awareness of diagnostic and nondrug therapeutic costs: a systematic review
    G Michael Allan
    University of Alberta, Alberta, Canada
    Int J Technol Assess Health Care 24:158-65. 2008
    ..g., syringes or intravenous tubing), and healthcare visits as well as to determine factors influencing awareness...
  43. ncbi Different conclusions about memantine
    Joel Lexchin
    Can Fam Physician 53:403-4; author reply 404. 2007
  44. ncbi Educating health professionals about drug and device promotion: advocates' recommendations
    Peter R Mansfield
    Healthy Skepticism Inc, Willunga, Australia
    PLoS Med 3:e451. 2006
  45. ncbi Inaccessibility of drug reports
    Joel Lexchin
    CMAJ 166:1251. 2002
  46. ncbi Drug advertising in medical journals
    Peter R Mansfield
    Lancet 361:879. 2003
  47. ncbi Patent law
    David Henry
    Lancet 361:1059. 2003
  48. ncbi Too much disclosure of product risks? CBC television, SOGC, and Diane-35
    Barbara Mintzes
    Centre for Health Services and Policy Research, University of British Columbia, Vancouver, BC, Canada
    J Obstet Gynaecol Can 25:268-9; discussion 270-3. 2003
  49. ncbi How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA
    Barbara Mintzes
    Centre for Health Services and Policy Research, and the Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC
    CMAJ 169:405-12. 2003
    ..We compared prescribing decisions in a US setting with legal DTCA and a Canadian setting where DTCA of prescription drugs is illegal, but some cross-border exposure occurs...
  50. ncbi Statistics can affect treatment decisions
    Joel Lexchin
    Can Fam Physician 49:1587; author reply 1587-8. 2003
  51. ncbi Clinical trials register
    Joel Lexchin
    Lancet 364:330. 2004
  52. ncbi Does the C in CME stand for "Continuing" or "Commercial"?
    Joel Lexchin
    CMAJ 172:160-2. 2005
  53. ncbi A hypertensive snow bird
    Joel Lexchin
    CMAJ 173:1357; discussion 1358. 2005
  54. ncbi Adverse drug events: counting is not enough, action is needed
    Elizabeth E Roughead
    Med J Aust 184:315-6. 2006
  55. ncbi Questions about Adderall XR
    Pierre Biron
    CMAJ 174:1303-4. 2006
  56. ncbi New directions in drug approval
    Joel Lexchin
    CMAJ 171:229-30. 2004
  57. ncbi Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey
    Barbara Mintzes
    Centre for Health Services and Policy Research, University of British Columbia, Vancouver BC, Canada V6T 1Z3
    BMJ 324:278-9. 2002